De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Sinopharm Group Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Sinopharm Group is de winst gegroeid met een gemiddeld jaarlijks percentage van 8.5%, terwijl de Healthcare industrie de winst jaarlijks groeide met 11.7%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 8.8% per jaar. Het rendement op eigen vermogen van Sinopharm Group is 11.4%, en het heeft een nettomarge van 1.5%.
Belangrijke informatie
8.5%
Groei van de winst
7.8%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 11.3% |
| Inkomstengroei | 8.8% |
| Rendement op eigen vermogen | 11.4% |
| Nettomarge | 1.5% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23
The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend
Feb 18
Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?
Feb 03Opbrengsten en kosten
Opbrengsten en kosten
Hoe Sinopharm Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 590,346 | 8,653 | 26,802 | 0 |
| 31 Mar 24 | 598,318 | 8,884 | 26,981 | -25 |
| 31 Dec 23 | 596,570 | 9,054 | 26,775 | 0 |
| 30 Sep 23 | 591,686 | 8,765 | 26,639 | 50 |
| 30 Jun 23 | 591,626 | 8,936 | 26,657 | 0 |
| 31 Mar 23 | 570,067 | 8,688 | 25,995 | 34 |
| 31 Dec 22 | 552,148 | 8,526 | 25,346 | 0 |
| 30 Sep 22 | 546,147 | 7,914 | 24,584 | 84 |
| 30 Jun 22 | 533,403 | 7,870 | 24,276 | 0 |
| 31 Mar 22 | 528,383 | 7,970 | 23,884 | 19 |
| 31 Dec 21 | 521,051 | 7,759 | 23,656 | 0 |
| 30 Sep 21 | 510,091 | 7,930 | 24,049 | 29 |
| 30 Jun 21 | 501,770 | 7,874 | 23,652 | 0 |
| 31 Mar 21 | 482,281 | 7,591 | 22,942 | 15 |
| 31 Dec 20 | 456,415 | 7,187 | 21,873 | 0 |
| 30 Sep 20 | 440,194 | 6,615 | 21,135 | 0 |
| 30 Jun 20 | 427,372 | 6,174 | 20,430 | 0 |
| 31 Mar 20 | 424,494 | 5,918 | 20,144 | -5 |
| 31 Dec 19 | 425,273 | 6,251 | 19,797 | 0 |
| 30 Sep 19 | 406,394 | 6,311 | 18,856 | 22 |
| 30 Jun 19 | 382,717 | 6,012 | 18,128 | 0 |
| 31 Mar 19 | 360,760 | 6,087 | 16,903 | 11 |
| 31 Dec 18 | 344,526 | 5,834 | 16,235 | 0 |
| 30 Sep 18 | 336,113 | 5,523 | 15,420 | 75 |
| 30 Jun 18 | 334,060 | 5,606 | 15,580 | 0 |
| 31 Mar 18 | 318,414 | 5,083 | 14,416 | 22 |
| 31 Dec 17 | 308,354 | 5,572 | 13,353 | 0 |
| 30 Sep 17 | 288,855 | 5,217 | 12,094 | 0 |
| 30 Jun 17 | 269,356 | 4,861 | 10,836 | 0 |
| 31 Mar 17 | 264,691 | 4,996 | 10,875 | 0 |
| 31 Dec 16 | 258,388 | 4,635 | 10,744 | 0 |
| 30 Sep 16 | 251,401 | 4,515 | 10,512 | 0 |
| 30 Jun 16 | 244,414 | 4,394 | 10,279 | 0 |
| 31 Mar 16 | 234,499 | 3,885 | 9,964 | 0 |
| 31 Dec 15 | 228,673 | 3,772 | 9,755 | 0 |
| 30 Sep 15 | 222,513 | 3,548 | 9,504 | 0 |
| 30 Jun 15 | 216,353 | 3,323 | 9,254 | 0 |
| 31 Mar 15 | 207,865 | 3,037 | 8,890 | 0 |
| 31 Dec 14 | 200,131 | 2,875 | 8,681 | 0 |
| 30 Sep 14 | 190,883 | 2,719 | 8,447 | 0 |
| 30 Jun 14 | 181,635 | 2,564 | 8,212 | 0 |
| 31 Mar 14 | 174,251 | 2,407 | 7,899 | 0 |
| 31 Dec 13 | 166,866 | 2,250 | 7,586 | 0 |
Kwaliteitswinsten: 1099 heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (1.5%) 1099 } zijn lager dan vorig jaar (1.5%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van 1099 is de afgelopen 5 jaar met 8.5% per jaar gegroeid.
Versnelling van de groei: De winstgroei 1099 is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.
Winst versus industrie: 1099 had het afgelopen jaar een negatieve winstgroei ( -3.2% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Healthcare ( -14.3% ).
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 11.4% ) van 1099 wordt als laag beschouwd.